Antileishmanial agent-41
Antileishmanial agent-41 (Compound 20k) is a selective Antileishmanial agent with a IC50 of 1.51 μg/mL against Leishmania donovani. Antileishmanial agent-41 increases ROS levels. Antileishmanial agent-41 can be used for the research of leishmaniasis.
For research use only. We do not sell to patients.
- Formula: C16H16F3N5O
- Molecular Weight:351.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Parasite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Leishmania 1.51 μg/mL (IC50) |
In Vitro
Antileishmanial agent-41 (48 h) exhibits moderate cytotoxicity against RAW 264.7 murine macrophages, with a CC50 value of 6.72 μg/mL[1].
Antileishmanial agent-41 (2-16 μg/mL; 48 h) potently inhibits the growth of Leishmania donovani promastigotes, with an IC50 of 1.51 μg/mL[1].
Antileishmanial agent-41 (1.51 μg/mL; 48 h) induces significant G0/G1 subphase cell cycle arrest in promastigotes of Leishmania donovani[1].
Antileishmanial agent-41 (1.51 μg/mL; 48 h) significantly increases the intracellular reactive oxygen species level in promastigotes of *Leishmania donovani*. After treatment at its IC50 concentration for 48 h, it induces a 5.66-fold increase compared with the untreated control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Leishmania donovani promastigotes
-
Concentration:1.51 μg/mL (IC50 concentration)
-
Incubation Time:48 h
-
Result:Significantly increased the proportion of L. donovani promastigotes in the sub-G0/G1 phase to 65.0% (p < 0.001), compared to 6.8% in untreated controls.
Showed cell cycle arrest comparable to amphotericin B and higher than miltefosine.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 24-25 g)[1]
-
Dosage:0.5 mg/kg; 1 mg/kg; 2 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:p.o.; single dose
-
Result:Showed no mortality, abnormal behavior, or visible toxicity signs across all dose groups.
Exhibited negligible body weight changes.
Demonstrated no significant hematological alterations compared to controls.
Revealed normal tissue architecture in liver, spleen, and kidney, with only minor, non-significant alterations in the 10 and 20 mg/kg groups.
Caused slightly elevated serum urea, creatinine, uric acid, cholesterol, triglycerides, HDL, LDL, VLDL, ALT, AST, and ALP levels versus controls at 10 and 20 mg/kg, with all values remaining within reference ranges.
Showed no significant biochemical signs of toxicity in the 0.5 and 1 mg/kg groups.
Chemical Information
-
Molecular Weight 351.33
-
Formula C16H16F3N5O
-
SMILES
NC1=NC2=CC=C(NC(C(F)(F)F)=O)C=C2C3=CC(CCCC)=NN31
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antileishmanial agent-41 Related Classifications
HY-183290 Related Classifications
Powered by Bioz
Keywords
- Antileishmanial agent-41
- Antileishmanial agent41
- Antileishmanial agent 41
- Parasite
- Reactive Oxygen Species (ROS)
- programmed-like parasite death
- BALB/c mice
- sub-G0/G1 phase
- RAW 264.7 murine macrophages
- epithelial cells
- Leishmania donovani promastigotes
- intracellular reactive oxygen species
- immune cells
- visceral leishmaniasis
- Inhibitor
- inhibitor
- inhibit